Evaluating the effect of prophylactic Acetaminophen in the prevention PDA (Patent Ductus Arteriosus) in premature neonates: The randomized clinical trial

Investigating the effect of prophylactic acetaminophen in the prevention of patent ductus arteriosus (PDA) in premature infants with a gestational age of less than 30 weeks.

In this randomized clinical trial study, premature newborn with gestational age less than 30 weeks who were admitted to the NICU of Imam Reza Hospital will be included in the study. The newborn will be randomly divided into case and control groups. A blind randomization will be done by sealed envelopes. Newborn in the intervention group will receive paracetamol a dose of 10 mg/kg every 6 hours for three days. Newborn in the control group (no placebo)

Randomized clinical trial study, premature newborn with gestational age less than 30 weeks who admitted to the NICU of Imam Reza Hospital. The babies will be randomly divided into case and control groups. A blind randomization will be done by sealed envelopes

Inclusion criteria: premature newborn with a gestational age of less than 30 weeks, premature babies who do not have evidence of patent ductus arteriosus. Exclusion criteria: CHF, Presence of liver or kidney disease or cholestasis, Presence of congenital heart disease, PPHN, Genetic disorder and congenital malformations, 5-minute Apgar score less than 5, pH < 7.2, septicemia, Sickness of the patient, The difference in pre-duct and post-duct oxygen saturation is more than 3%

In the intervention group, premature newborn with a gestational age of less than 30 weeks will receive injectable acetaminophen at 10 mg/kg every 6 hours for 3 days. In the control group (no placebo), premature newborn with a gestational age of less than 30 weeks will not receive any special drug.

The frequency of failure to develop patent ductus arteriosus in premature infants with a gestational age of less than 30 weeks

Random number table using www.sealedenvelope.com In the randomization part of the site, after selecting create a list, it specifies the number of 2 groups in block sizes of 5 and based on that, it presents the randomization list.

This study is an one-blind clinical trial where both the participants and all the researchers related to the patients are unaware of the patient's exposure.

All data can be shared after patients are made unidentified

data can be accessible 6 months after results are published

Data can be accessible through an email to the corresponding author

Data will be available for researchers in universities and other scientific institutions

After sending a request email to the corresponding author data will be sent in 2 month

Carrying out analysis on data is permitted